USDA selects Neogen to offer Campylobacter medium
Neogen Corporation was selected by the USDA to be
licensed to manufacture a new culture medium called Campy-Cefex to differentiate
different Campylobacter pathogens.
According to the company, Campy-Cefex
provides a quicker and simpler way to detect and
differentiate the pathogens Campylobacter jejuni and Campylobacter coli from
other, relatively harmless, members of the Campylobacter species.
Campy-Cefex is patented by the USDA's Agricultural Research Service
microbiologist Norman Stern, with the ARS Poultry Microbiological Safety
Research Unit in Athens, Ga. Stern's patented formulation uses the antibiotics
cycloheximide and cefoperazone, and has been shown by the USDA to both grow
Campylobacter in a culture and repress the growth of most other microorganisms.
Consequently, it was determined that the additional antibiotics previously used
with other Campylobacter media were not needed.
â€œWe're very pleased to have been chosen to manufacture and market
Campy-Cefex, a culture medium that the USDA has shown to provide superior
performance in detecting the most dangerous strains of Campylobacter,â€ said Ed
Bradley, Neogen's vice president of Food Safety. â€œAs a partner to numerous
poultry production operations, there is an added bit of confidence in offering a
medium from the USDA as we work with the regulators to help ensure our
customers' poultry products are safe as they can be.â€
To comment, login here
Or register to be able to comment.